Clinical trials on cholesteryl ester transfer protein (CETP) inhibitors revealed elevated sHDL-C but unexpected increases in cardiovascular mortality [92], potentially attributable to cholesterol-overloaded high-density lipoprotein particles (HDL-P), compensation with sHDL-C reverse transport dysfunction, and endothelial dysfunction [93]. Here, CETP is linked to endothelial dysfunction.